Horizon Europe · Europäische Union

Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and…

Full title in the source: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses

Offen

Das EU-Programm Horizon Europe plant 4 Förderungen mit 9 Mio. € – 10 Mio. € pro Projekt bei einem Gesamtbudget von 37,3 Mio. €. Die Einreichungsfrist endet am 17. Februar 2027 (EU-Ausschreibungen enden meist um 17:00 Uhr Brüsseler Zeit). Organisationen aus EU-Mitgliedstaaten und assoziierten Ländern wie der Türkei können in der Regel teilnehmen; maßgeblich sind die Bedingungen des Topics.

Frist: 17. Februar 2027 (in 94 Tagen)
Fördersumme: 9 Mio. € – 10 Mio. € pro Projekt
Gesamtbudget: 37,3 Mio. €
Förderquote: 100 % der förderfähigen Kosten Standardregel des Programms; die Ausschreibung kann abweichen.
Gesamtbudget: 37,3 Mio. €
Erwartete Förderungen: 4
Maßnahmentyp: HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
Wahrscheinliche Antragstellende: Unternehmen, KMU / Start-ups, Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber: Horizon Europe (HORIZON)
Referenz: HORIZON-HLTH-2027-01-DISEASE-07
Ausschreibung: HORIZON-HLTH-2027-01
Zuletzt geprüft: 14. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Erwartete Ergebnisse

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.

• Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.

Umfang

Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics.

This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy [1] .

Applicants should explicitly state in their proposal which of the following viruses is targeted and the proposed work should address only this specific virus. The proposed work should aim to advance the development of existing prophylactic and therapeutic monoclonal antibody candidates targeting exclusively one of the following viruses:

Vollständigen Text lesen

• Ebola Virus

• Marburg Virus

• Crimean-Congo Hemorrhagic Fever Virus

• Rift Valley Fever Virus

• Enterovirus D68

• Chikungunya Virus

Proposals should focus on antibodies produced or derived from a single cell clone through recombinant expression, such as B-cell derived antibodies, hybridoma derived antibodies and nanobodies.

Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.

Proposals should address all the following research areas:

• If necessary, finalisation of the in-vitro characterisation of existing monoclonal antibody candidates with regard to target specificity, epitope recognised, and their ability to impair or inactivate viral functions.

• In-vivo tests in at least one animal model or, if available in humanised immune system animal models, to demonstrate the protective function of the monoclonal antibodies deemed sufficient for moving to first clinical trials.

• If requested by regulators as pre-requisite for clinical studies, in-vivo tests in a non-human primate model.

• Evaluation of Antibody-Dependent Enhancement (ADE) risk where scientifically relevant.

• Production of batches of the most promising antibody candidates according to the Good Manufacturing Practices (GMP) [2] .

• First in human clinical safety studies demonstrating a clear regulatory pathway for market authorisation. Attention should be paid to critical biological and social factors such as sex, age, ethnicity and disability.

Participation of third countries where viruses addressed in the proposal are endemic or where outbreaks have occurred or are ongoing is encouraged.

The participation of start-ups, micro, small and medium-sized enterprises (SMEs) [3] is encouraged with the aim of…

Wer kann sich bewerben?

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Chikingunya Clinical development, Phase I Clinical trials Crimean Congo Haemorrhagic Fever Disease control Drug development, clinical phases Emerging Epidemics Epidemiology Infectious diseases Public health and epidemiology Viral Haemorrhagic Fevers Viruses Chikungunya Congo Crimean Ebola Enterovirus Filo Marburg Nairo

Zeitplan

Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

So bewerben Sie sich

Lesen Sie das vollständige Topic im Portal: erwartete Ergebnisse, Umfang, Maßnahmentyp und die Teilnahmebedingungen einschließlich Länder- oder Konsortialvorgaben.
Registrieren Sie jede Partnerorganisation im EU Funding & Tenders Portal, um einen PIC zu erhalten.
Verbundprojekte in Forschung und Innovation benötigen in der Regel mindestens drei unabhängige Partner aus drei verschiedenen EU-Mitgliedstaaten oder assoziierten Ländern. Prüfen Sie die Regel für dieses Topic.
Bereiten Sie Teil A (Verwaltungsformulare und Budget im Portal) und Teil B (technische Beschreibung auf der offiziellen Vorlage für diesen Maßnahmentyp) vor.
Reichen Sie vor dem Fristende am Stichtag im Portal ein. Verspätete Anträge werden nicht angenommen.

From the call text

Who can apply: Not stated in the call text we hold — check the official page
Company stage: Not stated in the call text we hold — check the official page
Single applicant or consortium: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where applicants must be based: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where to apply: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

EU-Leitfaden zur Antragstellung lesen

Offizielle Quellen

Offizielle Ausschreibungsseite

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 14. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.